Journal of Cachexia, Sarcopenia and Muscle | 2019
Psoas muscle fluorine‐18‐labelled fluoro‐2‐deoxy‐d‐glucose uptake associated with the incidence of existing and incipient metabolic derangement
Abstract
Skeletal muscle glucose utilization is an important component of whole‐body glucose consumption in normal humans. Fluorine‐18‐labelled fluoro‐2‐deoxy‐d‐glucose (18F‐FDG) is a non‐invasive molecular imaging probe for evaluating tissue glucose utilization. It remains unclear whether or not 18F‐FDG uptake by skeletal muscle has utility as a biomarker for metabolic derangement. We investigated the utility of measurement of muscle 18F‐FDG positron emission tomography/computed tomography uptake as a surrogate marker for existing and incipient metabolic abnormalities.